Navigation Links
Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
Date:7/17/2013

8211; Boehringer Ingelheim 19

3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance 20

3.1.11 Heat Map – Marketed Products Overview 21

4 COPD Pipeline 23

4.1 Overview 23

4.2 Mechanisms of Action in the Pipeline 25

4.3 Clinical Trials 27

4.3.1 Failure Rate 27

4.3.2 Clinical Trial Duration 33

4.3.3 Clinical Trial Size 35

4.4 Promising Pipeline Molecules 38

4.4.1 Umeclidinium Bromide – GlaxoSmithKline 38

4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance 38

4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance 39

4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim 39

4.4.5 TD-4208 – Theravance 40

4.4.6 QVA-149 – Novartis 40

4.4.7 Andolast (CR 2039) – Rottapharm | Madaus 41

4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 41

5 Market Forecast to 2019 47

5.1 Geographical Markets 47

5.1.1 Global Market 49

5.1.2 United States 51

5.1.3 Top Five Countries of Europe 54

5.1.4 Japan 58

5.2 Drivers and Barriers for the COPD Market 60

5.2.1 Drivers 60

5.2.2 Barriers 61

6 Strategic Consolidations 62

6.1 Major Co-development Deals 62

6.1.1 Galapagos Enters into Strategic Alliance with Roche 63

6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 63

6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed 63

6.2 Major Licensing Deals 64

6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 67

6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 68

6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401 68


'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
2. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
3. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
4. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
7. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
8. Remote Patient Monitoring Devices Market to 2017 - Chronic Disease Prevalence and Government Curbs on Hospital Spending to Drive the Market
9. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  PARI Respiratory Equipment has ... ® .  Kitabis Pak, approved by the FDA on December ... with a PARI LC PLUS ® Nebulizer for patients ... the hard work we put into this unique product offering ... is easy for patients to use, we also wanted to ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
(Date:6/3/2015)... , June 3, 2015 Mylan N.V. (Nasdaq: ... the Company will present at Goldman Sachs 36 th ... presentation is scheduled to begin at 4 p.m. PT / ... a live webcast of the presentation via the investor relations ... Mylan is a global pharmaceutical company committed to setting ...
Breaking Medicine Technology:Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... (NYSE: SHP ) ("ShangPharma" or the "Company"), a ... today announced that it will release its unaudited financial results ... May 19, 2011. Management will host a conference call to ... 19, 2011 (8:00pm Beijing time on May 19, 2011). ...
... 2011 Mithridion, Inc., a privately-owned clinical stage drug ... disorders, announces that the U.S. Food and Drug Administration ... lead drug candidate, for the treatment of Progressive Supranuclear ... to seven years of market exclusivity upon approval of ...
Cached Medicine Technology:ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 3
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the pain-balm segment, with a market share of 70 ... Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu ... SmithKline India (GSK) has decided to transfer its Iodex ... a GSK subsidiary. SKBCH has a strong marketing and ...
... the most common cancer among women. It accounts for ... more than 23,000 new cases diagnosed in 2001. Progestin ... the highest// level of protection against ovarian cancer. Analysis ... study showed that the pill can help prevent ovarian ...
... disease that affects at least 39 million Americans, and ... to describe the problem. One in five Americans is ... raises the risk of many potentially fatal health conditions//, ... is linked to at least 300,000 deaths in the ...
... studying eight cross-gender heart transplants from New York Medical ... the heart after injury.// The research explodes the long-standing ... finding has implications for heart disease treatment. ... damaged heart much as it does other organs came ...
... non-steroidal anti-inflammatory drug (NSAID) treatment has shown that ... the risk of ulcer formation.// Treatment with omeprazole ... infections and reduced the six-month ulcer probability of ... to 12 per cent in the NSAID-treated arthritis ...
... discovered molecules in the body that can protect ... research, the research could potentially lead to the ... been linked with ailments such as cardiovascular disease, ... and Alzheimer’s disease. ,The researchers from ...
Cached Medicine News:
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: